Bone Marrow Transplantation for Acute Non-Lymphoblastic Leukemia

References

• Rees J. K., Gray R. G., Swirsky D., Hayhoe F. G. Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial. Lancet 1986; 2: 1236–41
   PubMed Web of Science ®Google Scholar
• Preisler H., Anderson K., Rai K., et al. The frequency of long-term remission in patients with acute myelogenous leukaemia treated with conventional maintenance chemotherapy: a study of 760 patients with a minimal follow-up time of 6 years. Brit. J. Haematol. 1989; 71: 189–194
   PubMed Web of Science ®Google Scholar
• Thomas E. D., Buckner C. D., Rudolph R. H., et al. Allogeneic marrow grafting for hematologic malignancy using HL-A matched donor-recipient sibling pairs. Blood 1971; 38: 267–87
   PubMed Web of Science ®Google Scholar
• Thomas E. D., Buckner C. D., Banaji M., et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 1977; 49: 511–33
   PubMed Web of Science ®Google Scholar
• Thomas E., Buckner C., Clift R., et al. Marrow transplantation for acute nonlymphoblastic leukemia (ANLL) in first remission. N. Engl. J. Med. 1979; 301: 597–599
   PubMed Web of Science ®Google Scholar
• Clift R. A., Buckner C. D., Thomas E. D., et al. The treatment of acute nonlymphoblastic leukemia by allogeneic marrow transplantation. Bone Marrow Transplant 1987; 2: 243–58
   PubMed Web of Science ®Google Scholar
• Ebmt Allogeneic bone marrow transplantation for leukaemia in Europe. Lancet 1988; 1: 1379–82
   PubMed Web of Science ®Google Scholar
• Gratwohl A., Gahrton G. Allogeneic bone marrow transplantation in leukemia. Acta Oncol 1988; 27: 557–65
   PubMed Web of Science ®Google Scholar
• Ringden O., Sundberg B., Lonnqvist B., et al. Allogeneic bone marrow transplantation for leukemia: factors of importance for long-term survival and relapse. Bone Marrow Transplant 1988; 3: 281–90
   PubMed Web of Science ®Google Scholar
• Buckner C. D., Sanders J., Appelbaum F. R. Allogeneic marrow transplantation for acute non-lymphoblas-tic leukemia: first remission versus after first relapse. Bone Marrow Transplant 1989; 1: 244–6
   Google Scholar
• Gale R., Bortin M., Van Bekkum D., et al. Risk factors for acute graft-versus-host disease. Br. J. Haematol. 1987; 67: 397–406
   PubMed Web of Science ®Google Scholar
• Beatty P., Clift R., Mickelson E., et al. Marrow transplantation from related donors other than HLA-identical siblings. N. Engl. J. Med. 1985; 313: 765–771
   PubMed Web of Science ®Google Scholar
• Horowitz M., Ash R., Bach P., et al. Outcome of bone marrow transplantation using related donors other than HLA-identical siblings. Bone Marrow Transplant 1989; 4(suppl 2)38
   Google Scholar
• Tallman M. S., Kopecky K. J., Amos D., et al. Analysis of prognostic factors for the outcome of marrow transplantation of further chemotherapy for patients with acute nonlymphocytic leukemia in first remission. J. Clin. Oncol. 1989; 7: 326–37
   PubMed Web of Science ®Google Scholar
• Forman S. J., Krance R. A., O'Donnell M. R., et al. Bone marrow transplantation for acute nonlymphoblastic leukemia during first complete remission. An analysis of prognostic factors. Transplantation 1987; 43: 650–3
   PubMed Web of Science ®Google Scholar
• Aschan J., Ringden O., Tollemar J., et al. Improved survival in marrow recipients above 30 years of age with better prevention of graft-versus-host disease. Transplant Proc 1990; 22: 195–197
   PubMed Web of Science ®Google Scholar
• Thomas E., Storb R., Clift R., et al. Bone marrow transplantation. N. Engl. J. Med. 1975; 292: 832–843, 895-902
   PubMed Web of Science ®Google Scholar
• Ringdén O., Bäckman L., Lönnqvist B., et al. A randomized trial comparing the use of cyclosporin and methotrexate for graft-versus-host disease prophylaxis in bone marrow transplant recipients with hematologic malignancies. Bone Marrow Transplant 1986; 1: 41–51
   PubMed Web of Science ®Google Scholar
• Storb R., Deeg H. J., Fisher L., et al. Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia long-term follow-up of three controlled trials. Blood 1988; 71: 293–298
   PubMed Web of Science ®Google Scholar
• Atkinson K., Biggs J., Concannon A., et al. A prospective randomized trial of cyclosporin versus methotrexate after HLA-identical sibling marrow transplantation for patients with acute leukemia in first remission: analysis 2.5 years after last patient entry. Australian J. Med. 1988; 18: 594–599
   PubMedGoogle Scholar
• Prentice H., Blacklock H., Janossy G., et al. Depletion of T-lymphocytes in donor marrow prevents significant graft-versus-host disease in matched allogeneic leukaemic marrow transplant recipients. Lancet 1984; 1: 472–476
   PubMed Web of Science ®Google Scholar
• Storb R., Deeg H. J., Pepe M., et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 1989; 73: 1729–34
   PubMed Web of Science ®Google Scholar
• Storb R., Deeg H., Whitehead J., et al. Marrow transplantation for leukemia and aplastic anemia: two controlled trials of a combination of methotrexate and cyclosporine versus cyclosporine alone or methotrexate alone for prophylaxis of graft-versus-host disease. Transplant Proc 1987; 19: 2608–2613
   PubMed Web of Science ®Google Scholar
• Weiden P., Sullivan K., Flournoy N., et al. Antileukemic effect of chronic graft-versus-host disease. Contribution of improved survival after allogeneic marrow transplantation. N. Engl. J. Med. 1981; 304: 1529–1535
   PubMed Web of Science ®Google Scholar
• Weiden P., Flournoy N., Thomas E., et al. Antileukemic effect of graft-versus host disease in human recipients of allogeneic marrow grafts. N. Engl. J. Med. 1979; 300: 1068–1073
   PubMed Web of Science ®Google Scholar
• Horowitz M., Gale R., Sondel P. Graft- versus-leukemia reactions following bone marrow transplantation in humans. Blood 1990; 75: 555–562
   PubMed Web of Science ®Google Scholar
• Sullivan K. M., Storb R., Buckner C. D., et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N. Engl. J. Med 1989; 320: 828–34
   PubMed Web of Science ®Google Scholar
• Slavin S., Ackerstein A., Naparstek E., Or R., Weiss L. Hypothesis: The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD. Bone Marrow Transplant 1990; 6: 155–161
   PubMed Web of Science ®Google Scholar
• Goldman J., Gale R., Horowitz M., et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increase risk of relapse associated with T-cell depletion. Ann. Intern. Med 1988; 108: 806–814
   PubMed Web of Science ®Google Scholar
• Ringdén O., Pihlstedt P., Markling L., et al. Prevention of graft-versus-host disease with T-cell depletion of cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients. Bone Marrow Transplant 1991; 7: 221–226
   PubMed Web of Science ®Google Scholar
• Aschan J., Ringden O., Sundberg B., et al. Methotrexate combined with cyclosporin A decreases graft-versus-host disease but increases leukemic relapse compared to monotherapy. Bone Marrow Transplant 1991; 7: 113–119
   PubMed Web of Science ®Google Scholar
• Bacigalupo A., van Lint M. T., Occhini D., et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 1991; 77: 1423–8
   PubMed Web of Science ®Google Scholar
• Deeg H. J., Sullivan K. M., Buckner C. D. Marrow transplantation for acute nonlymphoblastic leukemia in first remission: toxicity and long-term follow-up of patients conditioned with single dose or fractionated total body irradiation. Bone Marrow Transplant 1986; 151–7
   PubMed Web of Science ®Google Scholar
• Clift R., Buckner G., Appelbaum F., et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regiments. Blood 1990; 76: 1867–1871
   PubMed Web of Science ®Google Scholar
• McClave P., Haake R., Bostrom B. Allogeneic bone marrow transplantation for acute non-lymphoblastic leukemia in first remission. Blood 1988; 72: 1512–1517
   PubMed Web of Science ®Google Scholar
• Brochstein J. A., Kernan N. A., Groshen S., et al. Allogeneic bone marrow transplantation after hyperfractio-nated total-body irradiation and cyclophosphamide in children with acute leukemia. A'. Engl. J. Med. 1987; 317: 1618–24
   PubMed Web of Science ®Google Scholar
• Helenglass G., Powles R. L., McElwain T. J., et al. Melphalan and total body irradiation (TBI) versus cyclophosphamide and TBI as conditioning for allogeneic matched sibling bone marrow transplants for acute myeloblasts leukaemia in first remission. Bone Marrow Transplant 1988; 3: 21–9
   PubMed Web of Science ®Google Scholar
• Raemaekers J., De Witte T., Schattenberg A., Van der Lely N. Prevention of leukemic relapse after transplantation with lymphocyte depleted marrow by intensification of the conditioning regimen with a six day continuous infusion of anthracyclins. Bone Marrow Transplant 1989; 4: 167–171
   PubMed Web of Science ®Google Scholar
• Geller R. B., Saral R., Piantadosi S., et al. Allogeneic bone marrow transplantation after high-dose busulfan and cyclophosphamide in patients with acute nonlymphocytic leukemia. Blood 1989; 73: 2209–18
   PubMed Web of Science ®Google Scholar
• Copelan E., Biggs J., Thompson J., et al. A multiinstitutional trial of BuCy2 followed by allogeneic marrow transplantation in AML. Experiment Hematol. 1990; 18: 706, abstract No. 596
   Google Scholar
• Tutschka P. J., Copeland E. A., Kapoor N., Avalos B. R., Klein J. P. Allogeneic bone marrow transplantation for leukemia using chemotherapy as conditioning: 6-year results of a single institution trial. Transplant Proc. 1991; 23: 1709–10
   PubMed Web of Science ®Google Scholar
• Maraninchi D., Blaise D., Guyotat D., et al. A prospective study randomizing Cy-TBI vs little BuCy prior allogeneic bone marrow transplantation (BMT) for acute myeloid leukemia (AML) in first complete remission (CR). Exp. Hematol. 1990; 18: 706, (Abstract No. 597)
   Google Scholar
• Aurer I., Gale R. Are new conditioning regimens for transplants in acute myelogenous leukemia better. Bone Marrow Transplant 1991; 7: 255–261
   PubMed Web of Science ®Google Scholar
• Petersen F. B., Buckner C D., Appelbaum F. R., et al. Busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study. Bone Marrow Transplant 1989; 4: 617–23
   PubMed Web of Science ®Google Scholar
• Blume K. G., Forman S. J., O'Donnell M. R., et al. Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies. Blood 1987; 69: 1015–20
   PubMed Web of Science ®Google Scholar
• Schmitz N., Gassmann W., Rister M., et al. Fractionated total body irradiation and high-dose VP 16-213 followed by allogeneic bone marrow transplantation in advanced leukemias. Blood 1988; 72: 1567–73
   PubMed Web of Science ®Google Scholar
• Bostrom B., Weisdorf D. J., Kim T., Kersey J. H., Ramsay N. K. Bone marrow transplantation for advanced acute leukemia: a pilot study of high- energy total body irradiation, cyclophosphamide and continuous infusion etoposide. Bone Marrow Transplant 1990; 5: 83–9
   PubMed Web of Science ®Google Scholar
• Riddell S., Appelbaum F. R., Buckner C. D., et al. High-dose cytarabine and total body irradiation with or without cyclophosphamide as a preparative regimen for marrow transplantation for acute leukemia. J. Clin. Oncol. 1988; 6: 576–82
   PubMed Web of Science ®Google Scholar
• Goldstone A. H., Anderson C. C., Linch D. C., et al. Autologous bone marrow transplantation following high dose chemotherapy for the treatment of adult patients with acute myeloid leukaemia. Br. J. Haematol. 1986; 64: 529–37
   PubMed Web of Science ®Google Scholar
• Burnett A. K., Tansey P., Watkins R., et al. Transplantation of unpurged autologous bone-marrow in acute myeloid leukaemia in first remission. Lancet 1984; 2: 1068–70
   PubMed Web of Science ®Google Scholar
• Carella A. M., Gaozza E., Santini G., et al. Autologous unpurged bone marrow transplantation for acute nonlymphoblastic leukaemia in first complete remission. Bone Marrow Transplant 1988; 3: 537–41
   PubMed Web of Science ®Google Scholar
• Björkstrand B., Ljungman P., Malm C., . Autologous Bone Marrow Transplantation. Proceedings of the Fifth Symposium, K. Dicke, J. Armitage, M. Dicke-Evinger, et al. University of Nebraska, Medical Center, USA., Omaha, Nebraska 1991; 81–89, Autologous bone marrow transplantation with nonpurged marrow in acute non-lymphoblastic leukemia
   Google Scholar
• Rowley S. D., Jones R. J., Piantadosi S., et al. Efficacy of ex vivo purging for autologous bone marrow transplantation in the treatment of acute nonlymphoblastic leukemia. Blood 1989; 74: 501–6
   PubMed Web of Science ®Google Scholar
• Yeager A. M., Kaizer H., Santos G. W., et al. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. N. Engl. J. Med. 1986; 315: 141–7
   PubMed Web of Science ®Google Scholar
• Yeager A. M., Rowley S. D., Kaizer H., Santos G. W. Ex vivo chemopurging of autologous bone marrow with 4-hydroperoxycyclophosphamide to eliminate occult leukemic cells. Laboratory and clinical observations. Am. J. Pediatr. Hematol. Oncol 1990; 12: 245–56
   PubMedGoogle Scholar
• Mangoni L., Carlo-Stella C., Caffo O., . Autologous bone marrow transplantation (ABMT) in acute non-lymphoid leukemia (ANLL) in first remission: Effect of mafosfamide purging with standard versus adjusted dose. Autologous Bone Marrow Transplantation, Proceedings of the Fifth Symposium, E. Dicke, J. Armitage, M. Dicke-Evinger, et al. University of Nebraska Medical Center, Omaha, Nebraska 1991; 43–54
   Google Scholar
• Gorin N. C., Aegerter P., Auvert B., et al. Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European survey of the role of marrow purging. Blood 1990; 75: 1606–14
   PubMed Web of Science ®Google Scholar
• Gribben J. G., Goldstone A. H., Linch D. C., MacMillan A. K., Richards J. D. Double autologous bone marrow transplantation in acute myeloid leukaemia. Bone Marrow Transplant 1989; 1: 209–11
   Google Scholar
• McMillan A. K., Goldstone A. H., Linch D. C., et al. High-dose chemotherapy and autologous bone marrow transplantation in acute myeloid leukemia. Blood 1990; 76: 480–8
   PubMed Web of Science ®Google Scholar
• Meloni G., De Fabritiis P., Papa G., et al. Cryopreserved autologous bone marrow infusion following high dose chemotherapy in patiets with acute myeloblastic leukemia in first relapse. Leuk. Res. 1985; 9: 407–12
   PubMed Web of Science ®Google Scholar
• Meloni G., De Fabritiis P., Petti M. C., Mandelli F. BAVC regimen and autologous bone marrow transplantation in patients with acute myelogenous leukemia in second remission. Blood 1990; 75: 2282–5
   PubMed Web of Science ®Google Scholar
• Reiffers J., Stoppa A., Rigal-Huguet F., et al. Allogeneic versus autologous bone marrow transplantation for treatment of acute myeloid leukemia in first complete remission (BGM 84 and BGMT 87 studies). Cortina d'Ampezzo 1991; 47, Abstract No. 86
   Google Scholar
• Hermans J., Suciu S., Stijnen T., et al. Treatment of acute myelogenous leukemia. An EBMT-EORTC retrospective analysis of chemotherapy versus allogeneic or autologous bone marrow transplantation: see comments. Eur. J. Cancer Clin. Oncol. 1989; 25: 545–50
   PubMedGoogle Scholar
• Appelbaum F. R., Fisher L. D., Thomas E. D. Chemotherapy v marrow transplantation for adults with acute nonlymphocytic leukemia: a five-year follow-up. Blood 1988; 72: 179–84
   PubMed Web of Science ®Google Scholar
• Appelbaum F. R., Dahlberg S., Thomas E. D., et al. Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison. Ann. Intern. Med. 1984; 101: 581–8
   PubMed Web of Science ®Google Scholar
• Löwenberg B., Verdonck L. J., Dekker A. W., et al. Autologous bone marrow transplantation in acute myeloid leukemia in first remission: results of a Dutch prospective study. J. Clin. Oncol. 1990; 8: 287–94
   PubMed Web of Science ®Google Scholar
• Hows J., Bradley B. The use of unrelated marrow donors for transplantation. Br. J. Haematol. 1990; 76: 1–6
   PubMed Web of Science ®Google Scholar
• Beatty P. The world experience with unrelated donor transplants. Bone Marrow Transpi 1991; 7(Suppl 1)54–58
   PubMedGoogle Scholar
• van Rood J. J. for the Editorial board of the BMDW. Bone Marrow Donors World Wide, 6th Edition. 1991
   Google Scholar
• Bradley B., Gore S., Howard M., Hows J. International Marrow Unrelated Search and Transplant (IMUST) Study. Bone Marrow Transpi. 1989; 4(Suppl 1)79
   PubMedGoogle Scholar
• Beatty P., Hansen J., Longton G., et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation 1991; 51: 443–447
   PubMed Web of Science ®Google Scholar
• Gajewsky J., Ho G., Feig S., Hunt L., Kaufman N., Champlin R. Bone marrow transplantation using unrelated donors for patients with advanced leukemia or bone marrow failure. Transplantation 1990; 50: 244–249
   PubMed Web of Science ®Google Scholar
• Phillips G. The use of unrelated donors (UD) for allogenic bone marrow transplantation (BMT): a pilot study for the Canadian BMT group. Bone Marrow Transplant 1991; 7: 52–53
   PubMed Web of Science ®Google Scholar
• Gahrton G. Comment and Critique. Bone Marrow Transplantation Using Unrelated Volunteer Donors. European Journal of Cancer 1991, in press
   PubMed Web of Science ®Google Scholar
• Ljungman P., de Witle Verdunck T. L., et al. Allogeneic (BMT) and autologous (ABMT) bone marrow transplantation for acute non-lymphoblastic leukemia (ANLL): a prospective analysis from HLA-typin. Blood 1991; 78(suppl. 1)291
   Google Scholar